S
Sentien Biotechnologies
A Cambridge, MA and Lexington, MA based regenerative medicine company developing cell based therapies for critical care diseases
About Sentien Biotechnologies
Sentien Biotechnologies, Inc. is a clinical-stage regenerative medicine company founded in 2008 by Biju Parekkadan and Brian Miller. The company is focused on developing cell-based therapies for conditions caused by systemic, immune-mediated inflammation. Miller, the current CEO, has over 20 years of experience in the life sciences, including roles at FORMA Therapeutics and Eli Lilly and Company. Parekkadan, the scientific co-founder, is a researcher whose work on a novel method to deliver cell therapy led to the company's core technology.
The company's business is centered on its proprietary ex-vivo cell therapy platform. The lead product, SBI-101, is an extracorporeal device that combines allogeneic mesenchymal stromal cells (MSCs) with a blood filtration device. This approach avoids the direct injection of cells into the patient. Instead, the patient's blood is circulated through the device, where it is "conditioned" by anti-inflammatory and regenerative factors secreted by the MSCs. This method allows for a controlled, sustained, and dynamic delivery of the therapeutic factors, a significant advantage over traditional cell infusion methods where cells are often lost quickly. The technology is designed to integrate with existing blood-circuit equipment like dialysis or ECMO machines.
Sentien's primary market is critical care, targeting complex systemic inflammatory diseases where single-factor agents have been ineffective. The company's initial focus is on treating patients with acute kidney injury (AKI) who require dialysis. Following promising initial data, the application of SBI-101 was expanded to clinical trials for treating severe COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and AKI. The company's revenue model will likely be based on the sale of the SBI-101 device for use in hospital and critical care settings. Sentien has secured a total of $13 million in funding over two rounds, with a notable $12 million Series A round in 2017 led by Boehringer Ingelheim Venture Fund and Mission BioCapital.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Sentien Biotechnologies is 540 monthly website visits, up 20% over the last three months. Sentien Biotechnologies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sentien Biotechnologies in the Lexington ecosystem
The Sentien Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US National Science Foundation
US Department of Health and Human Services
Series A5 investors entered at this stage
- BIBioInnovation
Boehringer Ingelheim Venture Fund
Chiesi Ventures- MCMBL Venture Capital
- MAMass Medical Angels
Other known investors4 additional known investors
Massachusetts Institute of Technology
Rutgers university
DRIVe - Division of Research, Innovation, and Ventures
Mission BioCapital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sentien Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sentien Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









